Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1902
- Registration Number
- NCT00092690
Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 655
- Registration Number
- NCT00092716
Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 6000
- Registration Number
- NCT00092703
A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 500
- Registration Number
- NCT00092768
Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2904
- Registration Number
- NCT00092586
An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1104
- Registration Number
- NCT00092664
Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)
Phase 3
Completed
- Conditions
- Coronary DiseaseHypercholesterolemia
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 410
- Registration Number
- NCT00092599
An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)
Phase 3
Completed
- Conditions
- HypercholesterolemiaCoronary Disease
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 450
- Registration Number
- NCT00092638
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)
Phase 3
Completed
- Conditions
- HypercholesterolemiaCoronary Disease
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 372
- Registration Number
- NCT00092612
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)
Phase 3
Completed
- Conditions
- HypercholesterolemiaCoronary Disease
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 442
- Registration Number
- NCT00092625